{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:43:33Z","timestamp":1790729013550,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.03.011","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T20:51:29Z","timestamp":1710622289000},"page":"2695-2706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial"],"prefix":"10.1016","volume":"42","author":[{"given":"Carlos","family":"Fierro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Weidenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Vidojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darja","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarina","family":"Gafoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Stroukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Zwiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Volkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.03.011_b0005","unstructured":"Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD). Eastern Equine Encephalitis Virus. June 13, 2023. Accessed July 2023. https:\/\/www.cdc.gov\/easternequineencephalitis\/index.html ."},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2024.03.011_b0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.vetmic.2009.08.023","article-title":"Encephalitic alphaviruses","volume":"140","author":"Zacks","year":"2010","journal-title":"Vet Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.011_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0025-7125(16)30270-X","article-title":"Viral encephalitis","volume":"77","author":"Bale","year":"1993","journal-title":"Med Clin North Am"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.011_b0020","doi-asserted-by":"crossref","first-page":"380","DOI":"10.30802\/AALAS-CM-18-000027","article-title":"Comparison of aerosol- and percutaneous-acquired venezuelan equine encephalitis in humans and nonhuman primates for suitability in predicting clinical efficacy under the animal rule","volume":"68","author":"Rusnak","year":"2018","journal-title":"Comp Med"},{"key":"10.1016\/j.vaccine.2024.03.011_b0025","doi-asserted-by":"crossref","unstructured":"Phelps AL, O'Brien LM, Eastaugh LS, Davies C, Lever MS, Ennis J, Zeitlin L, Nunez A, Ulaeto DO. Aerosol infection of Balb\/c mice with eastern equine encephalitis virus; susceptibility and lethality. Virol J. 2019;16(1):2. Published 2019 Jan 5. doi:10.1186\/s12985-018-1103-7.","DOI":"10.1186\/s12985-018-1103-7"},{"key":"10.1016\/j.vaccine.2024.03.011_b0030","unstructured":"GlobalSecurity.org. Weapons of Mass Destruction: Venezuelan Equine Encephalitis Virus. July 24, 2011. https:\/\/premium.globalsecurity.org\/wmd\/intro\/bio_vee.htm?ezoic_amp=1 (accessed Apr.2023)."},{"key":"10.1016\/j.vaccine.2024.03.011_b0035","first-page":"001","article-title":"Vaccine development for biothreat alpha viruses","volume":"1","author":"Spurgers","year":"2011","journal-title":"J Bioterr Biodef S"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2024.03.011_b0040","doi-asserted-by":"crossref","first-page":"D80","DOI":"10.1016\/j.vaccine.2009.07.095","article-title":"Vaccines for venezuelan equine encephalitis","volume":"27","author":"Paessler","year":"2009","journal-title":"Vaccine"},{"issue":"4 Suppl","key":"10.1016\/j.vaccine.2024.03.011_b0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7205\/MILMED.170.4S.92","article-title":"History of U.S. military contributions to the study of viral encephalitis","volume":"170","author":"Hoke","year":"2005","journal-title":"Mil Med"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.011_b0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.011_b0055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4269\/ajtmh.1963.12.597","article-title":"Use of an attenuated strain of venezuelan equine encephalomyelitis virus for immunization in man","volume":"12","author":"McKinney","year":"1963","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.011_b0060","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1128\/jcm.19.3.429-431.1984","article-title":"Protective efficacies of live attenuated and formaldehyde-inactivated venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters","volume":"19","author":"Jahrling","year":"1984","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.011_b0065","first-page":"24","article-title":"Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures","volume":"195","author":"Mayr","year":"1964","journal-title":"Zentralbl Bakteriol Orig"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2024.03.011_b0070","first-page":"375","article-title":"The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author\u2019s transl)","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene Erste Abteilung Originale Reihe B: Hygiene, Betriebshygiene, praventive Medizin"},{"issue":"29","key":"10.1016\/j.vaccine.2024.03.011_b0075","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2013.04.050","article-title":"Safety and immunogenicity of IMVAMUNE\u00ae smallpox vaccine using different strategies for a post event scenario","volume":"31","author":"Frey","year":"2013","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2024.03.011_b0080","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.vaccine.2014.02.043","article-title":"Phase II randomized, double-blinded comparison of a single high dose (5\u00d710(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1\u00d710(8) TCID50) in healthy vaccinia-na\u00efve individuals","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.011_b0085","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects","volume":"207","author":"Greenberg","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.011_b0090","doi-asserted-by":"crossref","unstructured":"Greenberg RN, Hurley MY, Dinh DV, Mraz S, Vera JG, von Bredow D, von Krempelhuber A, Roesch S, Virgin G, Arndtz-Wiedemann N, Meyer TP, Schmidt D, Nichols R, Young P, Chaplin P. A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis [published correction appears in PLoS One. 2015;10(11):e0142802. Hurley, Yadira [corrected to Hurley, Maria Yadira]]. PLoS One. 2015;10(10):e0138348. Published 2015 Oct 6. doi:10.1371\/journal.pone.0138348.","DOI":"10.1371\/journal.pone.0142802"},{"issue":"12","key":"10.1016\/j.vaccine.2024.03.011_b0095","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.011_b0100","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.011_b0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/135965350501000212","article-title":"Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption","volume":"10","author":"Harrer","year":"2005","journal-title":"Antivir Ther"},{"issue":"51","key":"10.1016\/j.vaccine.2024.03.011_b0110","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1016\/j.vaccine.2007.10.017","article-title":"Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by dryvax challenge","volume":"25","author":"Frey","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.011_b0115","doi-asserted-by":"crossref","first-page":"e0195897","DOI":"10.1371\/journal.pone.0195897","article-title":"Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: a randomised, double blind, placebo controlled phase III trial","volume":"13","author":"Overton","year":"2018","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.vaccine.2024.03.011_b0120","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.011_b0125","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.vaccine.2020.01.055","article-title":"Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: a randomized phase I clinical trial","volume":"38","author":"Samy","year":"2020","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.011_b0130","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1016\/j.vaccine.2020.01.058","article-title":"A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS","volume":"38","author":"Overton","year":"2020","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.011_b0135","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/jdv.13797","article-title":"Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis","volume":"30","author":"Darsow","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"43","key":"10.1016\/j.vaccine.2024.03.011_b0140","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.15585\/mmwr.mm7143e2","article-title":"Receipt of first and second doses of JYNNEOS vaccine for prevention of monkeypox - United States, may 22-october 10, 2022","volume":"71","author":"Kriss","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.vaccine.2024.03.011_b0145","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/infdis\/jit105","article-title":"Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial","volume":"207","author":"Walsh","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.011_b0150","doi-asserted-by":"crossref","unstructured":"Payne AB, Ray LC, Cole MM, Canning M, Houck K, Shah HJ, Farrar JL, Lewis NM, Fothergill A, White EB, Feldstein LR, Roper LE, Lee F, Kriss JL, Sims E, Spicknall IH, Nakazawa Y, Gundlapalli AV, Shimabukuro T, Cohen AL, Honein MA, Mermin J, Payne DC. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(49):1560-1564. Published 2022 Dec 9. doi:10.15585\/mmwr.mm7149a5.","DOI":"10.15585\/mmwr.mm7149a5"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.011_b0155","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41591-023-02229-3","article-title":"Real-world effectiveness of a single dose of mpox vaccine in males","volume":"29","author":"Wolff Sagy","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.vaccine.2024.03.011_b0160","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(23)00057-9","article-title":"Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study","volume":"23","author":"Bertran","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2024.03.011_b0165","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMoa2215201","article-title":"Vaccine effectiveness of JYNNEOS against mpox disease in the United States","volume":"388","author":"Deputy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.03.011_b0170","doi-asserted-by":"crossref","unstructured":"Dalton AF, Diallo AO, Chard AN, Moulia DL, Deputy NP, Fothergill A, Kracalik I, Wegner CW, Markus TM, Pathela P, Still WL, Hawkins S, Mangla AT, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen AP, Betancourt GS, Rowlands JV, Chai SJ, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel KA, Niccolai L, Castilho JL, Payne DC, Cohn AC, Feldstein LR. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(20):553-558. Published 2023 May 19. doi:10.15585\/mmwr.mm7220a3.","DOI":"10.15585\/mmwr.mm7220a3"},{"key":"10.1016\/j.vaccine.2024.03.011_b0175","doi-asserted-by":"crossref","unstructured":"Rosenberg ES, Dorabawila V, Hart-Malloy R, Anderson BJ, Miranda W, O'Donnell T, Gonzalez CJ, Abrego M, DelBarba C, Tice CJ, McGarry C, Mitchell EC, Boulais M, Backenson B, Kharfen M, McDonald J, Bauer UE. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(20):559-563. Published 2023 May 19. doi:10.15585\/mmwr.mm7220a4.","DOI":"10.15585\/mmwr.mm7220a4"},{"issue":"52","key":"10.1016\/j.vaccine.2024.03.011_b0180","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1016\/j.vaccine.2009.05.095","article-title":"Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain","volume":"27","author":"Suter","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.011_b0185","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line","volume":"238","author":"Carroll","year":"1997","journal-title":"Virology"},{"issue":"22","key":"10.1016\/j.vaccine.2024.03.011_b0190","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2024.03.011_b0195","doi-asserted-by":"crossref","unstructured":"Henning L, Endt K, Steigerwald R, Anderson M, Volkmann A. A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge. Front Immunol. 2021;11:598847. Published 2021 Jan 19. doi:10.3389\/fimmu.2020.598847.","DOI":"10.3389\/fimmu.2020.598847"},{"issue":"34","key":"10.1016\/j.vaccine.2024.03.011_b0200","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1016\/j.vaccine.2018.06.064","article-title":"Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses","volume":"36","author":"Hu","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.011_b9000","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41541-024-00842-y","article-title":"MVA-based vaccines are protective against lethal eastern equine encephalitis virus aerosol challenge in cynomolgus macaques","volume":"9","author":"Beddingfield","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.011_b0205","unstructured":"Bavarian Nordic. Jynneos Package Insert (2023). Apr. 2023. https:\/\/www.fda.gov\/media\/131078\/download (accessed Apr.2023)."},{"key":"10.1016\/j.vaccine.2024.03.011_b0210","unstructured":"Centers for Disease Control and Prevention. CDC Mpox 2022 Outbreak Cases and Data. Accessed July 2023. https:\/\/www.cdc.gov\/poxvirus\/mpox\/response\/2022\/index.html."},{"key":"10.1016\/j.vaccine.2024.03.011_b0215","unstructured":"European Centre for Disease Prevention and Control. Public health considerations for mpox in EU\/EEA countries. Accessed April 2023. [Online]. Available: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Public%20health%20considerations%20for%20mpox%20in%20EUEEA%20countries%202023_0.pdf."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24002962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24002962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T10:05:43Z","timestamp":1712138743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24002962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24002962"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.011","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}